MedPath

Safety and effectiveness assessment of Pluryal gel in the treatment of androgenic hair loss

Phase 2
Conditions
Androgenic alopecia.
Androgenic alopecia
Registration Number
IRCT20150101020514N15
Lead Sponsor
Tabesh Gostar Mehyad
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
20
Inclusion Criteria

Male or female aged 18-50 years
General health
Male with mild-moderate androgenic alopecia (II-IV Norwood Hamilton Scale)
Female with mild-moderate androgenic alopecia (I-II Ludwig Scale)
Voluntary participation and signing written informed consent

Exclusion Criteria

Chronic active scalp disease other than hair loss
Using any prescribed drug or OTC for hair loss within the past 3 months
Documented sensitivity to formulation components
Any severe weight loss or strict diet therapy during the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hair lost Changes, based on Global photographic review. Timepoint: First injection session (visit 0), week 6 and week 24. Method of measurement: One independent dermatologist will perform clinical assessments by scoring every photograph according to the Global photographic review scale .
Secondary Outcome Measures
NameTimeMethod
Hair count changes. Timepoint: First injection session (visit 0), week 6 and week 24. Method of measurement: Trichoscopy By Fotofinder.
© Copyright 2025. All Rights Reserved by MedPath